Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | NOS3 | P29474 | 2/20 | 0.37 |
| ▸ | NOS1 | P29475 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | STAT1 | P42224 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12267898 | 0.90 | HPGD (0.50) | HPGDLMNAL3MBTL1MAPTRAB9A | |
| SCHEMBL734544 | 0.84 | HPGD (0.48) | HPGDLMNAL3MBTL1MAPTRAB9A | |
| SCHEMBL14015459 | 0.80 | PLK1 (0.53) | HPGDSMN1; SMN2 | |
| SCHEMBL16501829 | 0.79 | PLK1 (0.47) | HPGDLMNAL3MBTL1KMT2ASMN1; SMN2 | |
| SCHEMBL182327 | 0.74 | CYP2C9 (0.55) | HPGDLMNAL3MBTL1MAPTRAB9A | |
| SCHEMBL9683939 | 0.74 | MAPT (0.50) | HPGDLMNAL3MBTL1MAPTRAB9A | |
| Hydrochloric Acid SCHEMBL5197216 | 0.73 | CYP2C9 (0.53) | HPGDLMNAL3MBTL1MAPTRAB9A | |
| SCHEMBL17319344 | 0.73 | MAPT (0.48) | HPGDLMNAL3MBTL1MAPTRAB9A | |
| SCHEMBL1262317 | 0.73 | MAPT (0.48) | HPGDLMNAL3MBTL1MAPTRAB9A | |
| SCHEMBL16659380 | 0.72 | MAPT (0.52) | HPGDLMNAL3MBTL1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170189441-A1 | DUAL MOLECULAR DELIVERY OF OLIGONUCLEOTIDES AND PEPTIDE CONTAINING CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170081425-A1 | PEPTIDE CONTAINING CONJUGATES FOR DUAL MOLECULAR DELIVERY OF OLIGONUCLEOTIDES | MERCK SHARP & DOHME CORP. (US) | 2017-03-23 | — | — | US | disclosed |
| US-9452221-B2 | Poly(acrylate) polymers for in vivo nucleic acid delivery | Arrowhead Pharmaceuticals, Inc. (US) | 2016-09-27 | — | — | US | disclosed |
| US-9089611-B2 | Poly(vinyl ester) polymers for in vivo nucleic acid delivery | Arrowhead Madison Inc. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20150110732-A1 | Poly(vinyl ester) Polymers for In Vivo Nucleic Acid Delivery | Arrowhead Madison Inc. | 2015-04-23 | — | — | US | disclosed |
| US-20150104408-A1 | Poly(acrylate) Polymers for In Vivo Nucleic Acid Delivery | Arrowhead Madison Inc. (US) | 2015-04-16 | — | — | US | disclosed |
| US-8658211-B2 | Polyconjugates for in vivo delivery of polynucleotides | Arrowhead Madison Inc. (US) | 2014-02-25 | — | — | US | disclosed |
| US-20120230938-A1 | Polyconjugates for In Vivo Delivery of Polynucleotides | Arrowhead Madison Inc. (US) | 2012-09-13 | — | — | US | disclosed |
| US-8138383-B2 | For cellular delivery; heterogeneity polymer containing cationic groups and hydrophobic groups | Arrowhead Madison Inc. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8008355-B2 | Delivering nucleic acids to cells; copolymer containing amine monomer and hydrophobic segments | ROCHE MADISON INC. (US) | 2011-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120230938-A1 | Polyconjugates for In Vivo Delivery of Polynucleotides | PHAX, NCL, PCBP1 | HPGD 4638/4885LMNA 281/4885L3MBTL1 773/4885 |
| US-20150110732-A1 | Poly(vinyl ester) Polymers for In Vivo Nucleic Acid Delivery | PHAX, PARG, PABPC4 | HPGD 4175/4885LMNA 342/4885L3MBTL1 174/4885 |
| US-20150104408-A1 | Poly(acrylate) Polymers for In Vivo Nucleic Acid Delivery | PHAX, PARN, PARG | HPGD 4559/4885LMNA 296/4885L3MBTL1 243/4885 |
| US-20170081425-A1 | PEPTIDE CONTAINING CONJUGATES FOR DUAL MOLECULAR DELIVERY OF OLIGONUCLEOTIDES | AGBL2, LNPEP, DCLRE1B | HPGD 4358/4885LMNA 1253/4885L3MBTL1 14/4885 |
| US-20170189441-A1 | DUAL MOLECULAR DELIVERY OF OLIGONUCLEOTIDES AND PEPTIDE CONTAINING CONJUGATES | DCLRE1A, DCLRE1B, LNPEP | HPGD 4623/4885LMNA 872/4885L3MBTL1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.